Corpus overview


MeSH Disease

Human Phenotype


    displaying 1 - 2 records in total 2
    records per page

    Acute Pancreatitis HP Pancreatitis MESHD may Occur in COVID-19 Patients with Clearance of SARS-CoV-2 in Lung: A Case Report

    Authors: Hong Zhao; Junwei Su; Kaijin Xu; Yu Shi; Yunqing Qiu; Jifang Sheng

    doi:10.21203/ Date: 2020-08-20 Source: ResearchSquare

    Background: Severe acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2), is mostly causes lung damages, but also lead to gastroenterology injury MESHD. SARS-CoV-2 - associated acute pancreatitis HP pancreatitis MESHD has been reported, however, clearance of SARS-CoV-2 and the pancreatitis HP pancreatitis MESHD was not clear.Case presentation: A 62 year old diabetic MESHD female TRANS patient suffer from coronavirus diseases MESHD (COVID-19) and detection of SARS-CoV-2 turned negative on day 11 and day 12 in sputum. Two days latter, the patient was diagnosed with acute pancreatitis HP acute pancreatitis MESHD. Through the support treatment, the patient got better and discharged from our hospital 18 days later.Conclusions: Our case provided an initial view of SARS-CoV-2 infection MESHD with acute pancreatitis HP pancreatitis MESHD and the acute pancreatitis HP pancreatitis MESHD may occur in COVID-19 patients with clearance of SARS-CoV-2 in lung.

    Patients with COVID-19 Interstitial Pneumonia HP Exhibit Pancreatic Hyperenzymemia MESHD and Not Acute Pancreatitis HP Pancreatitis MESHD

    Authors: Raffaele Pezzilli; Stefano Centanni; Michele Mondoni; Rocco F. Rinaldo; Matteo Davì; Rossana Stefanelli; GianVico Melzi d’Eril; Alessandra Barassi

    doi:10.21203/ Date: 2020-07-28 Source: ResearchSquare

    Background and aims: Gastrointestinal manifestations of COVID-19 have been well established, but pancreatic involvement MESHD is under debate. The aim of the study is to evaluate the presence of acute pancreatitis HP pancreatitis MESHD in COVID-19 patients and to assess the frequency of pancreatic hyperenzymemia MESHD. Methods: From April 1st 2020 to April 30th 2020, 110 consecutive patients (69 males TRANS, 41 females TRANS; mean age TRANS 63.0 years, range 24-93 years) met these criteria and were enrolled in the study.. The clinical data and serum SERO activity of pancreatic amylase and lipase were assayed in all patients using commercially available kits. Results: None of the patients studied developed clinical signs or morphological alterations compatible with acute pancreatitis HP pancreatitis MESHD. However, it was found that 24.5% of the patients had amylase values above 53 IU/L and 16.4% had lipase values above 300 IU/. Only one patient (0.9%) had both amylase and lipase values in excess of three-fold the upper normal limit without clinical signs of pancreatitis HP pancreatitis MESHD. Conclusions: The presence of pancreatic hyperenzymemia MESHD in a patient with COVID-19 requires the management of these patients be guided by clinical evaluation and not merely by evaluation of the biochemical results.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.



MeSH Disease
Human Phenotype

Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.